Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions-Reference-Cited by-同舟云学术

Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions

Published:2010-01-13 Issue:7 Volume:127 Page:1718-1726
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Laxmi Y.R. Santosh,Liu Xiaoping,Suzuki Naomi,Kim Sung Yeon,Okamoto Kanako,Kim Hyo Jeong,Zhang Guangxiang,Chen John J.,Okamoto Yoshinori,Shibutani Shinya

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference49 articles.

1. A current view of tamoxifen for the treatment and prevention of breast cancer;Jordan;Br J Pharmacol,1993

2. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study;Fisher;J Natl Cancer Inst,1998

3. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens;Killackey;Cancer Treat Rep,1985

4. Tamoxifen therapy for breast cancer and endometrial cancer risk;Bernstein;J Natl Cancer Inst,1999

5. Genotoxic mechanism of tamoxifen in developing endometrial cancer;Kim;Drug Metab Rev,2004

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer;Journal of Medicinal Chemistry;2020-11-02

2. Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer;RSC Medicinal Chemistry;2020

3. Carcinogenic potential of fluorinated estrogens in mammary tumorigenesis;Toxicology Letters;2020-01

4. Development of novel and safer anti-breast cancer agents, SS1020 and SS5020, based on a fundamental carcinogenic research;Genes and Environment;2019-03-28

5. Tricyclic Indazoles—A Novel Class of Selective Estrogen Receptor Degrader Antagonists;Journal of Medicinal Chemistry;2019-01-14